← Eichor
Condition: Plasmacytoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Plasmacytoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06429150Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · The General Hospital of Western Theater Command · NCT07519187Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 · 5 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07529782SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06863584A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell
Phase 1 · 14 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07179679Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825The Indiana Myeloma Registry
Phase N/A · 1 location(s) · Indiana University · NCT03616483A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
EARLY_Phase 1 · 2 location(s) · Peking University First Hospital · NCT067171133'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT0093509068Ga-BCMA PET/CT in Multiple Myeloma
Phase 2/Phase 3 · 5 location(s) · Peking University First Hospital · NCT07319897GR1803 Injection in Patients With RRMM
Phase 2 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT06952075Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infilt
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07115667Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Longitudinal Data Registry of Plasma Cell Dyscrasia
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT06760052Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT05248633Engineered Dendritic Cell Vaccines for Multiple Myeloma
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06435910CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT07416682
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.